Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon

A double blind placebo controlled trial

Research output: Contribution to journalArticle

Abstract

In order to determine the acute effect of nifedipine, a calcium channel blocker, on digital hemodynamics in patients with Raynaud's phenomenon, we studied 21 patients in a double blinded, placebo controlled trial. Digital blood flow at room temperature was measured by venous occlusion plethysmography as perfusion pressures were lowered by elevating the hand above the level of the heart. After placebo, there was a small reduction in digital blood flow without any alteration in the perfusion pressure. After nifedipine, there was a significant reduction in both perfusion pressure and digital blood flow at each level of hand elevation. When analyzed as pressure-flow relationships, there was no significant change after nifedipine, indicating that the fall in blood flow could be accounted for by the reduction in perfusion pressure. Four of the placebo group developed Raynaud's phenomenon after the baseline study, whereas none developed Raynaud's phenomenon after nifedipine. Our results suggest that although nifedipine may reduce vascular reactivity, caution is warranted in use of this drug in patients with threatened digital ischemia because of the possibility that digital blood flow may be reduced.

Original languageEnglish (US)
Pages (from-to)278-283
Number of pages6
JournalJournal of Rheumatology
Volume14
Issue number2
StatePublished - 1987

Fingerprint

Raynaud Disease
Nifedipine
Placebos
Perfusion
Pressure
Hand
Plethysmography
Calcium Channel Blockers
Blood Vessels
Ischemia
Hemodynamics
Blood Pressure
Temperature
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

@article{2d273660856745e2882074595980bc3c,
title = "Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: A double blind placebo controlled trial",
abstract = "In order to determine the acute effect of nifedipine, a calcium channel blocker, on digital hemodynamics in patients with Raynaud's phenomenon, we studied 21 patients in a double blinded, placebo controlled trial. Digital blood flow at room temperature was measured by venous occlusion plethysmography as perfusion pressures were lowered by elevating the hand above the level of the heart. After placebo, there was a small reduction in digital blood flow without any alteration in the perfusion pressure. After nifedipine, there was a significant reduction in both perfusion pressure and digital blood flow at each level of hand elevation. When analyzed as pressure-flow relationships, there was no significant change after nifedipine, indicating that the fall in blood flow could be accounted for by the reduction in perfusion pressure. Four of the placebo group developed Raynaud's phenomenon after the baseline study, whereas none developed Raynaud's phenomenon after nifedipine. Our results suggest that although nifedipine may reduce vascular reactivity, caution is warranted in use of this drug in patients with threatened digital ischemia because of the possibility that digital blood flow may be reduced.",
author = "Wise, {Robert A} and R. Malamet and Fredrick Wigley",
year = "1987",
language = "English (US)",
volume = "14",
pages = "278--283",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "2",

}

TY - JOUR

T1 - Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon

T2 - A double blind placebo controlled trial

AU - Wise, Robert A

AU - Malamet, R.

AU - Wigley, Fredrick

PY - 1987

Y1 - 1987

N2 - In order to determine the acute effect of nifedipine, a calcium channel blocker, on digital hemodynamics in patients with Raynaud's phenomenon, we studied 21 patients in a double blinded, placebo controlled trial. Digital blood flow at room temperature was measured by venous occlusion plethysmography as perfusion pressures were lowered by elevating the hand above the level of the heart. After placebo, there was a small reduction in digital blood flow without any alteration in the perfusion pressure. After nifedipine, there was a significant reduction in both perfusion pressure and digital blood flow at each level of hand elevation. When analyzed as pressure-flow relationships, there was no significant change after nifedipine, indicating that the fall in blood flow could be accounted for by the reduction in perfusion pressure. Four of the placebo group developed Raynaud's phenomenon after the baseline study, whereas none developed Raynaud's phenomenon after nifedipine. Our results suggest that although nifedipine may reduce vascular reactivity, caution is warranted in use of this drug in patients with threatened digital ischemia because of the possibility that digital blood flow may be reduced.

AB - In order to determine the acute effect of nifedipine, a calcium channel blocker, on digital hemodynamics in patients with Raynaud's phenomenon, we studied 21 patients in a double blinded, placebo controlled trial. Digital blood flow at room temperature was measured by venous occlusion plethysmography as perfusion pressures were lowered by elevating the hand above the level of the heart. After placebo, there was a small reduction in digital blood flow without any alteration in the perfusion pressure. After nifedipine, there was a significant reduction in both perfusion pressure and digital blood flow at each level of hand elevation. When analyzed as pressure-flow relationships, there was no significant change after nifedipine, indicating that the fall in blood flow could be accounted for by the reduction in perfusion pressure. Four of the placebo group developed Raynaud's phenomenon after the baseline study, whereas none developed Raynaud's phenomenon after nifedipine. Our results suggest that although nifedipine may reduce vascular reactivity, caution is warranted in use of this drug in patients with threatened digital ischemia because of the possibility that digital blood flow may be reduced.

UR - http://www.scopus.com/inward/record.url?scp=0023187962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023187962&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 278

EP - 283

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 2

ER -